Zhan Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhan Zheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Haibin Deng
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication- Haibin Deng
Oncology Department, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai, P. R. China
1 shared publication Jianwen Li
Shanghai
1 shared publication- Jianwen Li
China National Center for Food Safety Risk Assessment, Beijing 100022, China
1 shared publication - Li-Fang Wang
Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
1 shared publication Qijun Lu
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
1 shared publication
Latest Publications
- 19 November 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 168 (Pt 1) , 115844
Formosanin C inhibits infiltration of MDSCs by activating the STING pathway in non-small cell lung cancer
- 19 November 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 168 (Pt 1) , 115844
Formosanin C inhibits infiltration of MDSCs by activating the STING pathway in non-small cell lung cancer
- Open Access
- 1 August 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 276, 114196
Chinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy
- 1 August 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 276, 114196
Open AccessChinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy
- Open Access
- 29 March 2021
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 9
Cinobufagin-Loaded and Folic Acid-Modified Polydopamine Nanomedicine Combined With Photothermal Therapy for the Treatment of Lung Cancer
Cinobufagin is used as a traditional Chinese medicine for cancer therapy. However, it has some disadvantages, such as poor water solubility, short circulating half-life, and low bioavailability. In the present study, a targeted delivery and smart responsive polydopamine (PDA)-based nanomedicine for delivering cinobufagin was rationally designed to improve the anticancer efficacy of the compound for the treatment of lung cancer. The modification of the nanomedicine using folic acid first mediated tumor targeting via the interaction between folic acid and its receptors on tumor cells. After lysosomes escape, the PDA nanomedicine was triggered by the low pH and released its cargo into the tumor microenvironment. The nanomedicine had a better therapeutic effect against lung cancer when used in combination with photothermal therapy. Compared with other nanomedicines used with photothermal therapy, this nanocarrier was not only sensitive to biologically low pH levels for on-demand drug release, but was also biodegradable, breaking down into biocompatible terminal products. Therefore, the proposed drug delivery system with targeted delivery and smart release demonstrated potential as a multifunctional nanoplatform that can enhance the bioavailability and reduce the side effects of chemotherapeutic agents.
- 29 March 2021
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 9
Open AccessCinobufagin-Loaded and Folic Acid-Modified Polydopamine Nanomedicine Combined With Photothermal Therapy for the Treatment of Lung Cancer
Cinobufagin is used as a traditional Chinese medicine for cancer therapy. However, it has some disadvantages, such as poor water solubility, short circulating half-life, and low bioavailability. In the present study, a targeted delivery and smart responsive polydopamine (PDA)-based nanomedicine for delivering cinobufagin was rationally designed to improve the anticancer efficacy of the compound for the treatment of lung cancer. The modification of the nanomedicine using folic acid first mediated tumor targeting via the interaction between folic acid and its receptors on tumor cells. After lysosomes escape, the PDA nanomedicine was triggered by the low pH and released its cargo into the tumor microenvironment. The nanomedicine had a better therapeutic effect against lung cancer when used in combination with photothermal therapy. Compared with other nanomedicines used with photothermal therapy, this nanocarrier was not only sensitive to biologically low pH levels for on-demand drug release, but was also biodegradable, breaking down into biocompatible terminal products. Therefore, the proposed drug delivery system with targeted delivery and smart release demonstrated potential as a multifunctional nanoplatform that can enhance the bioavailability and reduce the side effects of chemotherapeutic agents.